journal
Journals Journal of the Advanced Practi...

Journal of the Advanced Practitioner in Oncology

https://read.qxmd.com/read/38196672/characterization-and-management-of-adverse-reactions-in-patients-with-unresectable-hepatocellular-carcinoma-treated-with-lenvatinib
#1
JOURNAL ARTICLE
Anna Jones, Paola Degregorio, Max W Sung, Zahra Ramji, Min Ren, Ari D Baron
AIMS: Advanced practice providers (APPs) play a vital role in monitoring for and managing adverse reactions (ARs). As lenvatinib ARs can resemble cirrhosis (commonly presenting with hepatocellular carcinoma [HCC]), APP input is important for timely detection and management of ARs and to promote medication adherence. DESIGN: The goal of this post-hoc analysis of the REFLECT trial was to characterize key ARs associated with lenvatinib, and to discuss management strategies...
November 2023: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/38196671/capecitabine-for-salvage-treatment-of-patients-with-heavily-pretreated-human-papillomavirus-associated-oropharynx-cancer-with-distant-metastases
#2
JOURNAL ARTICLE
Anna C Cooper, Casey A Fazer, Ashish V Chintakuntlawar, Harry E Fuentes Bayne, Patrick W McGarrah, Katharine A R Price
BACKGROUND: Patients with metastatic human papillomavirus-associated oropharyngeal cancer (HPV-OPC) have a median overall survival exceeding 2 years and are often candidates for multiple lines of palliative therapy. With the approval of immunotherapy as first-line treatment, salvage therapeutic options are limited. We describe our experience using capecitabine as salvage therapy for patients with recurrent or metastatic (R/M) HPV-OPC. METHODS: We performed a retrospective study of patients with R/M HPV-OPC with distant metastatic disease...
November 2023: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/38196670/mitigating-burnout-transition-to-a-condensed-workweek-for-advanced-practice-providers-in-infectious-diseases
#3
JOURNAL ARTICLE
Shannon Holloway, Kelly McConn, Roy Borchardt, Victor E Mulanovich, Javier A Adachi
Burnout among health-care workers is highly prevalent and profoundly impacts the quality of patient care. In addition to affecting patient safety, burnout results in higher staff turnover, revenue deficits due to decreased productivity, financial risk, and diminished organization viability because of the impact on quality of care, patient satisfaction, and safety. Culmination of external and internal stressors in health-care worker populations is associated with a higher probability of burnout and workers who reported perceived low workplace flexibility...
November 2023: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/38196669/when-germline-genetic-testing-results-are-unclear-highlighting-variants-of-uncertain-significance
#4
JOURNAL ARTICLE
Patricia Kelly, Suzanne Mahon, Patricia Friend
With the advent of high-throughput next-generation sequencing (NGS) and multigene panel testing, genetic testing and interpretations have become increasingly complex. Specifically, reports demonstrating "variant of uncertain significance" (VUS) present interpretative challenges. Misinterpretation of a VUS may result in clinical harm, emotional distress for patients and family members, and potential health-care provider liability. The following article and deidentified case study illustrate how a lack of health-care provider and patient understanding of a germline VUS resulted in a negative patient outcome and unnecessary surgery...
November 2023: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/38196668/role-of-preemptive-cytomegalovirus-hyperimmunoglobulin-in-cytomegalovirus-viremia-following-stem-cell-transplant-an-integrative-review
#5
REVIEW
Jaci Whittaker, Ashley Martinez, Joyce E Dains
INTRODUCTION: Cytomegalovirus (CMV) is a major cause of morbidity and mortality in stem cell transplant (SCT) patients. Cytomegalovirus hyperimmunoglobulin (CMV-HIG) therapy has been described in the solid organ transplant setting. However, no review has focused on preemptive use of intravenous CMV immunoglobulins in the SCT setting. This review aims to consolidate findings regarding the preemptive use of CMV-HIG for CMV viremia in SCT patients. METHODS: PubMed and Scopus were searched using specific search criteria for publications from 2011 to 2021...
November 2023: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/38196667/clinical-utility-of-the-31-gene-expression-profile-test-on-the-management-of-cutaneous-melanoma-by-nurse-practitioners-and-physician-assistants
#6
JOURNAL ARTICLE
Renata Block, Deborah Patterson, Jennifer J Siegel, Brian Martin, Ann P Quick, Jillian Hunt
OBJECTIVE: The 31-gene expression profile (31-GEP) can predict the risk of recurrence and metastasis in cutaneous melanoma (CM). We assessed the viewpoints and use of 31-GEP testing by physician assistants (PAs) and nurse practitioners (NPs) for patients with CM. METHODS: NPs and PAs ( n = 369) completed an 18-question online survey about their viewpoints and use of the 31-GEP risk-stratification test. RESULTS: Most practitioners ( n = 334, 90...
November 2023: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/38196666/impact-of-fasting-on-patients-with-cancer-an-integrative-review
#7
REVIEW
Samantha Thompson, Lydia T Madsen, Angela Bazzell
BACKGROUND: Patients with cancer often pursue nutrition as an avenue to positively impact their care management and disease outcomes. Nutritional interventions are increasing in popularity, especially intermittent fasting as an adjunct to chemotherapy. However, limited research is available on the impact of intermittent fasting on patients with cancer. METHODS: A comprehensive literature search was conducted using Ovid MEDLINE, Ovid EMBASE, and CINAHL databases...
November 2023: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/38196665/jadpro-live-2023-shaping-the-future-of-oncology
#8
EDITORIAL
Beth Faiman
No abstract text is available yet for this article.
November 2023: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/37808076/post-transplant-cyclophosphamide-for-the-prevention-of-graft-vs-host-disease-in-allogeneic-hematopoietic-cell-transplantation-a-guide-to-management-for-the-advanced-practitioner
#9
REVIEW
Ekaterina Kachur, Jai N Patel, Allison L Morse, Donald C Moore, Justin R Arnall
Cyclophosphamide remains a critical component to haploidentical transplant conditioning regimens. Post-transplant cyclophosphamide (PTCy) emerged as an effective component of graft-vs.-host disease (GVHD) prophylaxis in the nonmyeloablative haploidentical bone marrow transplant setting. The relative ease of administration compared with ex vivo manipulations and efficacy in reducing GVHD has led to increasing PTCy use in transplant centers around the world. The role of PTCy has expanded to haploidentical transplantation with myeloablative conditioning regimens and peripheral blood progenitor cells as the donor source...
September 2023: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/37808075/surgical-management-of-gastrointestinal-stromal-tumors
#10
JOURNAL ARTICLE
Heather Townsend
Gastrointestinal stromal tumors (GISTs) are considered rare, but they are one of the most common malignant mesenchymal tumors within the gastrointestinal tract, affecting 4,000 to 6,000 adults in the United States each year. Because gastrointestinal bleeding is often the initial symptom, a thorough and timely diagnostic workup is imperative to accurately diagnose a potentially deadly tumor. Endoscopic ultrasound is helpful when working through a differential diagnosis of subepithelial lesions and can help identify which mucosal layer the lesion originates from, as well as the density of the lesion; however, surgical resection is the standard of care for the treatment of a resectable nonmetastatic GIST...
September 2023: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/37808074/the-importance-of-endpoints-in-oncology-clinical-trials
#11
EDITORIAL
Beth Faiman
No abstract text is available yet for this article.
September 2023: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/37808073/precautions-for-patients-taking-tamoxifen-or-aromatase-inhibitors
#12
EDITORIAL
Mary Heery
No abstract text is available yet for this article.
September 2023: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/37808072/-my-choices-my-wishes-program-and-its-effect-on-chemotherapy-at-the-end-of-life-and-advance-care-directive-documentation
#13
JOURNAL ARTICLE
Jessica Tamar Davis
BACKGROUND: Oncology patients have tremendous symptom burden both physically and emotionally. Palliative care (PC) improves quality of life and prevents suffering. Advance care planning (ACP) empowers patients to articulate goals of their care. New guidelines call for palliative care to be provided and chemotherapy avoided the last 2 weeks of life. The American Society of Clinical Oncology (ASCO) recommends integrating palliative care within the oncology setting to achieve these outcomes...
September 2023: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/37808071/patient-reported-outcomes-with-belantamab-mafodotin-treatment-in-patients-with-triple-class-refractory-multiple-myeloma
#14
JOURNAL ARTICLE
Rakesh Popat, Sagar Lonial, Peter M Voorhees, Simona Degli Esposti, Boris Gorsh, Ira Gupta, Joanna Opalinska, Sandhya Sapra, Trisha Piontek, Zangdong He, David Kleinman, Debra Schaumberg, Antoine Regnault, Juliette Meunier, Laurie Eliason
In the randomized phase II DREAMM-2 study, single-agent belantamab mafodotin demonstrated deep and durable responses and a manageable safety profile in triple-class refractory relapsed/refractory multiple myeloma (RRMM). We present patient-reported outcomes (PROs) from this study for patients treated with the approved dose of belantamab mafodotin (2.5 mg/kg q3w). Disease and treatment-related symptoms, health-related quality of life (HRQOL), functioning, and patient-reported ocular changes were assessed using questionnaires (European Organisation for Research and Treatment of Cancer Quality of Life questionnaires EORTC-QLQ-C30 and EORTC-QLQ-MY20, Ocular Surface Disease Index [OSDI], and the National Eye Institute Visual Functioning Questionnaire 25 [NEI VFQ-25]) at baseline, during treatment (every 3 or 6 weeks), and at the end of treatment (EOT)...
September 2023: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/37808070/pancreatic-cancer-and-the-family-connection-the-role-of-advanced-practitioners-in-screening-and-educating-genetically-at-risk-individuals
#15
REVIEW
Tracy Lowe, Jane Deluca, Ludovico Abenavoli, Luigi Boccuto
Pancreatic cancer is the third leading cause of cancer deaths in the United States. It has a 95% mortality rate within 5 years of the initial diagnosis. Pancreatic ductal adenocarcinoma is the most commonly diagnosed histotype. The average age at diagnosis is 70 years. Familial forms of pancreatic cancer have been associated with pathogenic variants in predisposing genes, including ATM, BRCA1, BRCA2, PALB2, CDKN2A, STK11, MLH1 , and MSH2 . Collecting information on the patient's family history may serve as a primary tool to screen an individual's risk for familial pancreatic cancer...
September 2023: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/37576367/providing-care-during-cancer-drug-shortages
#16
EDITORIAL
Beth Faiman
No abstract text is available yet for this article.
July 2023: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/37576366/managing-drug-interactions-with-oral-anticancer-treatments
#17
JOURNAL ARTICLE
Lisa K Lohr, Kimball T Blake, Cindy M Chan, Sabrina Sturm, Gavyn T Walsh
The use of oral anticancer treatments is widespread and vital to modern cancer treatment. Novel oral chemotherapy and targeted therapy treatments continue to receive US Food and Drug Administration approval every year, making knowledge of these agents a necessity for practitioners working in oncology. Many oral anticancer agents are prone to drug interactions that can contribute to adverse effects and decrease therapy efficacy. Potential drug-drug interactions include (1) interactions with CYP3A4 inhibitors and inducers, (2) interactions related to gastric acid suppression, (3) interactions related to prolongation of the cardiac QT interval, (4) interactions related to anticoagulant medications, and (5) drug-food and drug-herb interactions...
July 2023: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/37576365/anti-spike-antibody-responses-in-allogeneic-stem-cell-transplant-recipients-to-two-doses-of-covid-19-mrna-vaccination-a-retrospective-single-center-analysis
#18
JOURNAL ARTICLE
Jaime L Shahan, Robert H Collins, Prapti Patel, Yazan F Madanat, Madhuri Vusirikala
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients were excluded from the initial SARS-CoV-2 mRNA vaccination efficacy trials. Suboptimal vaccine responses have been reported in immunocompromised cohorts such as patients with solid tumors or hematologic malignancies, suggesting the need for additional research. Widespread data on the antibody responses and vaccine efficacy in allo-HSCT recipients is limited. In our single-center, retrospective study, we analyzed the anti-spike IgG antibody responses in 75 allo-HSCT recipients who received a series of two doses of mRNA vaccination...
July 2023: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/37576364/silent-conversations-goals-of-care-and-end-of-life-quality-in-relapsed-high-risk-leukemia
#19
JOURNAL ARTICLE
Lacy Jo Graham, Amy Hite, Jennifer Harris, Greg Belcher
BACKGROUND: Advanced practice providers (APPs) affect high-quality health care through leadership, evidence-based practice implementation, and quality improvement projects. When planning solutions to clinical problems, leadership must solicit APP input to promote success. Hematology patients are more likely to receive poor-quality end-of-life (EOL) care than those with solid tumors. Regardless of disease, aggressive EOL care is increasing despite evidence that it is often inconsistent with patients' goals of care (GOC)...
July 2023: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/37576363/hyperammonemia-secondary-to-5-fluorouracil
#20
JOURNAL ARTICLE
Ashley Scott, Sreenivas V Rao, Mary Lou Affronti
5-fluorouracil (5-FU) is one of the most common adjuvant antineoplastic agents used in the treatment of localized and metastatic colon cancer. Frequent side effects of 5-FU include myelosuppression, mucositis, nausea, vomiting, and diarrhea. However, hyperammonemic encephalopathy is a rare neurologic toxicity that can occur after 5-FU chemotherapy administration. Patients with 5-FU-induced hyperammonemic encephalopathy often exhibit symptoms of altered mental status with no radiologic abnormalities or laboratory abnormalities except for significantly elevated ammonia levels with occasional lactic acidosis and respiratory alkalosis...
July 2023: Journal of the Advanced Practitioner in Oncology
journal
journal
48476
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.